Anthony V. Moorman

Anthony V. Moorman

Auto-generated profile, based on publicly available information

Anthony V. Moorman

Leukaemia Research Cytogenetics Group, Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2010 in Blood
Verified
Journal Article
Open access
PDF file
DGDavid Grimwade
David Grimwade
RHRobert K. Hills
Robert K. Hills
AMAnthony V. Moorman
Anthony V. Moorman
HWHelen Walker
Helen Walker
SCStephen Chatters
Stephen Chatters
OGon behalf of the National Cancer Research Institute Adult Leukaemia Working Group
on behalf of the National Cancer Research Institute Adult Leukaemia Working Group
Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic abnormalities remains uncertain. We studied the outcomes of 5876 patients (16-59 years of age) who were classified into 54 cytogenetic subgroups and treated in the Medical Research Council trials. In multivariable analysis, t(15;17)(q22;q21), t(8;21)(q22;q22), and inv(16)(p13q22)/t(16;16)(p13;q22) were the only abnormalities found to predict a relatively favorable prognosis (P < .001). In patients with t(15;17) treated with extended all-trans retinoic acid and anthracycline-based chemotherapy, additional cytogenetic changes did not have an impact on prognosis. Similarly, additional abnormalities did not have a significant adverse effect in t(8;21) AML; whereas in patients with inv(16), the presence of additional changes, particularly +22, predicted a better outcome (P = .004). In multivariable analyses, various abnormalities predicted a significantly poorer outcome, namely abn(3q) (excluding t(3;5)(q25;q34)), inv(3)(q21q26)/t(3;3)(q21;q26), add(5q)/del(5q), −5, −7, add(7q)/del(7q), t(6;11)(q27;q23), t(10;11)(p11∼13;q23), other t(11q23) (excluding t(9;11)(p21∼22;q23) and t(11;19)(q23;p13)), t(9;22)(q34;q11), −17, and abn(17p). Patients lacking the aforementioned favorable or adverse aberrations but with 4 or more unrelated abnormalities also exhibited a significantly poorer prognosis (designated “complex” karyotype group). These data allow more reliable prediction of outcome for patients with rarer abnormalities and may facilitate the development of consensus in reporting of karyotypic information in clinical trials involving younger adults with AML. This study is registered at http://www.isrctn.org as ISRCTN55678797 and ISRCTN17161961.

15 December 2010 in Nature
Verified
Journal Article
Closed access
KAKristina Anderson
Kristina Anderson
CLChristoph Lutz
Christoph Lutz
FDFrederik W. van Delft
Frederik W. van Delft
CBCaroline M. Bateman
Caroline M. Bateman
YGYanping Guo
Yanping Guo
MGMel Greaves
Mel Greaves

1 August 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
RHRobert K Hills
Robert K Hills
SCSylvie Castaigne
Sylvie Castaigne
FAFrederick R Appelbaum
Frederick R Appelbaum
JDJacques Delaunay
Jacques Delaunay
SPStephen Petersdorf
Stephen Petersdorf
ABAlan K Burnett
Alan K Burnett

14 December 2006 in Blood
Verified
Journal Article
Closed access
PDF file
AMAnthony V. Moorman
Anthony V. Moorman
CHChristine J. Harrison
Christine J. Harrison
GBGeorgina A. N. Buck
Georgina A. N. Buck
SRSue M. Richards
Sue M. Richards
LSLorna M. Secker-Walker
Lorna M. Secker-Walker
OGon behalf of the Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group
on behalf of the Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a significantly improved outcome. Multivariate analysis demonstrated that the prognostic relevance of t(8;14), complex karyotype, and Ho-Tr was independent of sex, age, white cell count, and T-cell status among Ph-negative patients. The observation that Ho-Tr and, for the first time, karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials.

24 September 2009 in Blood
Verified
Journal Article
Open access
PDF file
LRLisa J. Russell
Lisa J. Russell
MCMelania Capasso
Melania Capasso
IVInga Vater
Inga Vater
TATakashi Akasaka
Takashi Akasaka
OBOlivier A. Bernard
Olivier A. Bernard
CHChristine J. Harrison
Christine J. Harrison
We report 2 novel, cryptic chromosomal abnormalities in precursor B-cell acute lymphoblastic leukemia (BCP-ALL): a translocation, either t(X;14)(p22;q32) or t(Y;14)(p11;q32), in 33 patients and an interstitial deletion, either del(X)(p22.33p22.33) or del(Y)(p11.32p11.32), in 64 patients, involving the pseudoautosomal region (PAR1) of the sex chromosomes. The incidence of these abnormalities was 5% in childhood ALL (0.8% with the translocation, 4.2% with the deletion). Patients with the translocation were older (median age, 16 years), whereas the patients with the deletion were younger (median age, 4 years). The 2 abnormalities result in deregulated expression of the cytokine receptor, cytokine receptor-like factor 2, CRLF2 (also known as thymic stromal-derived lymphopoietin receptor, TSLPR). Overexpression of CRLF2 was associated with activation of the JAK-STAT pathway in cell lines and transduced primary B-cell progenitors, sustaining their proliferation and indicating a causal role of CRLF2 overexpression in lymphoid transformation. In Down syndrome (DS) ALL and 2 non-DS BCP-ALL cell lines, CRLF2 deregulation was associated with mutations of the JAK2 pseudokinase domain, suggesting oncogenic cooperation as well as highlighting a link between non-DS ALL and JAK2 mutations.

10 December 2009 in Blood
Verified
Journal Article
Open access
PDF file
DMDavid I. Marks
David I. Marks
EPElisabeth M. Paietta
Elisabeth M. Paietta
AMAnthony V. Moorman
Anthony V. Moorman
SRSusan M. Richards
Susan M. Richards
GBGeorgina Buck
Georgina Buck
HLHillard M. Lazarus
Hillard M. Lazarus
The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, χ2, P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.